白血病患者造血细胞磷酸酶与半胱氨酸蛋白酶基因表达及其临床意义

The expression and clinical significance of hematopoietic cell phosphatase and cysteinyl aspartate-specific proteinase in leukemia

目的探讨造血细胞磷酸酶(SHP1)基因和天冬酰胺特异酶切的半胱氨酸蛋白酶(Caspase1、3)基因表达与白血病患者的化疗效果的关系。方法用RTPCR方法检测白血病患者骨髓单个核细胞中SHP1和Caspase1、3的mRNA表达。结果急性白血病(AL)患者SHP1和Caspase1、3表达率分别为33.3%、80.0%、100.0%;慢性髓细胞白血病(CML)患者SHP1表达率在急变期、慢性期分别为0.0%、37.5%。SHP1和Caspase1、3基因阳性患者的首次完全缓解(CR)率分别为85.0%、64.3%、55.8%,明显高于阴性患者(分别为15.6%、20.0%),差异均有统计学意义(P<0.05);Caspase1、3与SHP1表达呈正相关。结论SHP1可能是一个潜在的抑癌基因,它可能是通过激活下游的凋亡基因Caspase1、3发挥作用;Caspase1、3与SHP1基因表达呈正相关且与病人的CR率有关,表明它们均参与了白血病的转归,可同时作为判断白血病患者的疗效和预后指标。

Objective To evaluate the relationship between the expression of hematopoietic cell phosphatase （SHP-1） gene or cysteinyl aspartate-specific proteinases （Caspase-1,3） gene and the effect of chemotherapy in leukemia patients. Methods The expression of SHP-1 and Caspase-1,3 gene was measured in leukemia patients with reverse transcriptase-polymerase chain reaction. Results The positive rate of SHP-1 and Caspase-1,3 gene in acute leukemia was 33.3%, 80. 0% and 100. 0%. The positive rate of SHP-1 in chronic myeloid leukemia （CML） -blastic phase and CML-chronie phase was O. 0%, 37.5%. The first complete remission（CR） rate of SHP-1 and Caspase-1,3 positive group was 85.0% ,64. 3% and 55.8% ,which were higher than that of SHP-1 and Caspase-1,3 negative group （ P 〈 0. 05 ）. There was a positive correlation between SHP-1 and Caspase-1,3. Conclusions SHP-1 gene is potentially an antioncogene and may play a role through activation of Caspase-1,3 gene. The expression of SHP-1 and Caspase- 1,3 is associated with remission rate and it is shown that they participate in the prognosis of leukemia. They could be used as indices for evaluating therapeutic efficacy and judging prognosis in leukemia patients.